Overview

This trial is active, not recruiting.

Condition breast cancer
Treatments ramucirumab (imc-1121b), docetaxel, placebo
Phase phase 3
Sponsor Eli Lilly and Company
Start date August 2008
End date March 2013
Trial size 1144 participants
Trial identifier NCT00703326, 13892, 2008-001727-65, CP12-0606, I4T-IE-JVBC, TRIO-012, TRIO-CIRG-012

Summary

The objective of this study is to compare the progression-free survival (PFS) of the drug combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated participants with human epidermal growth factor receptor 2 (HER2)-negative, unresectable, locally-recurrent or metastatic breast cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, investigator)
Primary purpose treatment
Arm
(Experimental)
ramucirumab (imc-1121b) IMC-1121B
Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
docetaxel
Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
(Placebo Comparator)
docetaxel
Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
placebo placebo
Placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.

Primary Outcomes

Measure
Progression-Free Survival (PFS)
time frame: Randomization to disease progression or death or until data cutoff of 31 Mar 2013 (up to 48 months)

Secondary Outcomes

Measure
Overall Survival (OS)
time frame: Randomization to death or until data cutoff of 31-Mar-2013 (up to 49 months)
Time to Progression (TTP)
time frame: Randomization to disease progression or until data cutoff of 31-Mar-2013 (up to 48 months)
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate)
time frame: Randomization to disease progression or until data cutoff of 31-Mar-2013 (up to 48 months)
Duration of Response
time frame: Date of first CR or PR to PD or death or until data cutoff date of 31-Mar-2013 (up to 35 months)
Total Functional Assessment of Cancer Therapy-Breast (FACT-B): Change From Baseline to End of Therapy
time frame: Baseline, End of Therapy or until data cutoff of 31-Mar-2013 (up to 42 months)
Number of Participants With Adverse Events
time frame: First dose to study completion (up to 49 months) plus 30-day safety follow-up

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - Participant is able to provide signed informed consent - Participant is female and ≥ 18 years of age or older if required by local laws or regulations - Participant has histologically or cytologically confirmed adenocarcinoma of the breast that is now metastatic or locally-recurrent and inoperable with curative intent. Every effort should be made to make paraffin-embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis - Participant has measurable and/or non-measurable disease - Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) or 0, 1+ overexpression by immunohistochemistry (IHC) - Participant has not received prior chemotherapy for metastatic or locally-recurrent and inoperable breast cancer - Participant completed (neo) adjuvant taxane therapy at least 6 months prior to randomization - Participant completed (neo) adjuvant biologic therapy at least 6 weeks prior to randomization - Participant completed all prior radiotherapy with curative intent ≥ 3 weeks prior to randomization - Participant may have received prior hormonal therapy for breast cancer in the (neo) adjuvant and/or the metastatic setting ≥ 2 weeks prior to randomization - Participant's left ventricular ejection fraction is within normal institutional ranges - Participant has resolution to grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3 (NCI-CTCAE v 3.0) of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy with the exception of peripheral neuropathy which must have resolved to grade ≤ 2 - Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 - Participant is amenable to compliance with protocol schedules and testing - Participant has adequate hematological functions [absolute neutrophil count (ANC) ≥ 1500 cells/microliter (mcL), hemoglobin ≥ 9 grams/deciliter (g/dL), and platelets ≥ 100,000 cells/mcL and ≤ 850,000 cells/mcL] - Participant has adequate hepatic function [bilirubin within normal limits (WNL), aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 times the upper limit of normal (ULN), or ≤ 5.0 times the ULN if the transaminase elevation is due to liver metastases, and alkaline phosphatase ≤ 5.0 times the ULN] - Participant has serum creatinine ≤ 1.5 x ULN. If serum creatinine > 1.5 x ULN the calculated creatinine clearance should be > 40 milliliters/minute (mL/min) - Participant's urinary protein is ≤ 1+ on dipstick or routine urinalysis (UA); if urine protein ≥ 2+, a 24-hour urine collection must demonstrate < 1000 milligrams (mg) of protein in 24 hours to allow participation in the study - Participant must have adequate coagulation function as defined by international normalized ratio (INR) ≤ 1.5 and a partial thromboplastin time (PTT) ≤ 1.5 X ULN if not receiving anticoagulation therapy. Participants on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight heparin and if on warfarin must have a INR between 2 and 3 and have no active bleeding (defined as within 14 days of randomization) or pathological condition that carries a high risk of bleeding (such as, tumor involving major vessels or known varices) - Women of childbearing potential must implement adequate contraception in the opinion of the investigator - Participant has not received prior biologic therapy for metastatic or locally recurrent and inoperable breast cancer Exclusion Criteria: - Participant has a concurrent active malignancy other than breast adenocarcinoma, adequately treated non melanomatous skin cancer, or other non-invasive carcinoma or in situ neoplasm. A participant with previous history of malignancy is eligible, provided that she has been disease free for > 3 years - Participant has a known sensitivity to docetaxel or other drugs formulated with polysorbate 80 - Participant has a known sensitivity to agents of similar biologic composition as ramucirumab or other agents that specifically target vascular endothelial growth factor (VEGF) - Participant has a history of chronic diarrheal disease within 6 months prior to randomization - Participant has received irradiation to a major bone marrow area as defined as > 25% of bone marrow (such as, pelvic or abdominal radiation) within 30 days prior to randomization - Participant has participated in clinical trials of experimental agents within 4 weeks prior to randomization - Participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders - Participant has active, high risk bleeding (such as, via gastric ulcers or gastric varices) within 14 days prior to randomization - Participant has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy - Participant has uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders in the opinion of the investigator - Participant has brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease - Participant has known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness - Participant has pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen. - Participant is pregnant or lactating

Additional Information

Official title A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
Description Female participants at least 18 years of age with histologically or cytologically confirmed, human epidermal growth factor receptor 2 (HER2) negative breast adenocarcinoma that is metastatic or locally-recurrent and inoperable with curative intent will be randomized. Participants may not have received chemotherapy for metastatic or locally-recurrent, inoperable breast cancer. It is anticipated that 1113 participants will be randomized with 371 participants in the docetaxel plus placebo arm and 742 participants in the docetaxel plus ramucirumab (IMC-1121B) arm. There will be approximately 250 centers in North and South America, Europe, Asia, Middle East, Africa, Australia, and New Zealand. On Day 1 of each 21-day cycle, participants will receive docetaxel 75 mg/m² as a one-hour I.V. infusion followed by either ramucirumab (IMC-1121B) 10 mg/kg or placebo 10 mg/kg as a one-hour I.V. infusion. Each cycle is repeated every 21 days. Treatment will continue until there is evidence of progressive disease, unacceptable toxicity, or other withdrawal criteria are met. Participants who discontinue study treatment with either ramucirumab (IMC-1121B) or placebo may continue to receive docetaxel. Similarly, participants who discontinue docetaxel therapy may continue to receive either ramucirumab (IMC-1121B) or placebo, whichever the participant was randomized to receive. All participants will be followed for survival at regularly scheduled intervals (every 6 weeks until progressive disease and every 6 months thereafter) for at least 36 months after discontinuing study therapy.
Trial information was received from ClinicalTrials.gov and was last updated in May 2014.
Information provided to ClinicalTrials.gov by Eli Lilly and Company.